Featured Research

from universities, journals, and other organizations

Unique study shows efficacy of imaging technology in evaluating heart drug dalcetrapib

Date:
September 12, 2011
Source:
The Mount Sinai Hospital / Mount Sinai School of Medicine
Summary:
Researchers have for the first time used several imaging techniques to prove the efficacy of a promising new treatment for atherosclerosis -- the build-up of plaque in artery walls that can lead to a heart attack.

Researchers from Mount Sinai School of Medicine have for the first time used several imaging techniques to prove the efficacy of a promising new treatment for atherosclerosis -- the build-up of plaque in artery walls that can lead to a heart attack. Using positron-emission tomography (PET)/computed tomography (CT) and magnetic resonance imaging (MRI), the research team showed that dalcetrapib, a novel treatment for atherosclerosis, prevented the progression of disease and reduced vascular inflammation over 24 months.

The data are published in the September 12 issue of The Lancet.

The dal-PLAQUE study is the longest placebo-controlled, active-drug MRI study to date, and the first to use a variety of noninvasive imaging techniques to visualize arterial plaque. In this Phase IIB, double-blind, multicenter trial, Mount Sinai researchers evaluated 130 study participants with atherosclerosis who were randomized to receive dalcetrapib or placebo for 24 months. To determine the efficacy of dalcetrapib, the team used MRI to analyze plaque progression in the arterial wall and PET/CT to assess arterial inflammation. The images showed that dalcetrapib significantly reduced atherosclerotic disease progression and inflammation.

"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said Zahi A. Fayad, PhD, Professor of Radiology and Medicine in the Division of Cardiology, and the Director of the Translational and Molecular Imaging Institute at Mount Sinai School of Medicine, and lead author on the study. "We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease."

Lowering of the so-called bad cholesterol (low-density lipoprotein) through statin use, is a highly effective method of improving cardiovascular outcome in a broad range of patients. However, despite optimal use, significant risk remains. Dalcetrapib is part of a class of drugs called cholesteryl ester transfer protein inhibitors that raise high-density lipoprotein (HDL) commonly known as "good" cholesterol. Research has shown that raising HDL cholesterol may reduce coronary artery disease risk. In the dal-PLAQUE study, patients who received dalcetrapib saw a 31 percent increase in HDL cholesterol levels, as examined through MRI. The PET/CT scans showed that inflammation levels in the carotid artery of patients taking dalcetrapib were significantly reduced, yet stayed the same in the placebo group.

"Considering the concerns surrounding this class of drugs, MRI and PET/CT imaging are valuable biomarkers for assessing safety and efficacy," said Dr. Fayad. "The first drug in this class, torcetrapib, effectively increased HDL cholesterol but caused a significant increase in mortality due to vascular inflammation. Through noninvasive imaging, we were able to determine that the inflammation associated with torcetrapib was not found in dalcetrapib. The success of this trial indicates that noninvasive imaging may be a critical tool for evaluating other investigational treatments for heart disease as well."

As a leader in cardiovascular medicine and imaging, Mount Sinai is establishing a center that will use state of the art imaging technology to help treat and prevent atherosclerosis, heart attack, and heart failure. In collaboration with the Mount Sinai Cardiovascular Institute and Mount Sinai Heart, the new Translational and Molecular Imaging Institute will continue to innovate, validate and translate new tools for the improvements of patients care.

"Cardiovascular disease impacts millions of people, and costs billions of dollars each year in the United States alone," said Valentin Fuster, MD, PhD, Director of Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at The Mount Sinai Medical Center. "As demonstrated in the dal-PLAQUE study, Dr. Fayad has brought Mount Sinai to the forefront of using noninvasive imaging to help study, prevent, and treat heart disease. We look forward to using MRI and PET/CT in future clinical trials."

The centers that participated in the dal-PLAQUE trial include: Baylor College of Medicine, Houston; Cardiovascular Imaging Technologies, Kansas; University of Minnesota; The Mount Sinai Medical Center, New York; University of Washington School of Medicine, Seattle; Jacksonville Center for Clinical Research; Iredell Internal Medicine; Sterling Research Group; Metabolic and Atherosclerosis Research Center, Cincinnati; William Beaumont Hospital Health Center; Montreal Heart Institute.

Dr. Fayad receives financial compensation as a scientific advisory board member for F. Hoffman-La Roche Ltd, the sponsor of this study.


Story Source:

The above story is based on materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt, Tracy Burgess, Valentin Fuster, Christie M Ballantyne, Evan A Stein, Jean-Claude Tardif, James H F Rudd, Michael E Farkouh, Ahmed Tawakol. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. The Lancet, 2011; DOI: 10.1016/S0140-6736(11)61383-4

Cite This Page:

The Mount Sinai Hospital / Mount Sinai School of Medicine. "Unique study shows efficacy of imaging technology in evaluating heart drug dalcetrapib." ScienceDaily. ScienceDaily, 12 September 2011. <www.sciencedaily.com/releases/2011/09/110912193259.htm>.
The Mount Sinai Hospital / Mount Sinai School of Medicine. (2011, September 12). Unique study shows efficacy of imaging technology in evaluating heart drug dalcetrapib. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2011/09/110912193259.htm
The Mount Sinai Hospital / Mount Sinai School of Medicine. "Unique study shows efficacy of imaging technology in evaluating heart drug dalcetrapib." ScienceDaily. www.sciencedaily.com/releases/2011/09/110912193259.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins